NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Large pharma have forgone Europe pricing and thus revenue because they wanted U.S. revenue and primary positioning on various indications, there’s no way in hell an expert like you would even know when LP (ceo of small biotech) would unblind, because:

If she had been told of (any potential) stat sig in 2015 she would have had to decide whether to stay blinded for higher/any European revenue versus trying her luck at u.s. approval on lesser maturity.

She told people in very late 2014 on the record, topline likely by early 2016.

Off the record, a couple weeks later, she supposedly told several people she would not stop trial until primary endpoint reached.

Good for you if you figured out what to do, but quit shaming people when you very well could have been wrong.